文献速递老年慢病共病管理衰弱、肌少症与跌倒

基于DNA甲基化的慢性系统性炎症替代生物标志物InfLaMeS

A novel DNA methylation-based surrogate biomarker for chronic systemic inflammation (Inflammation Latent Variable Methylation Surrogate, InfLaMeS).
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2025-01-01

研究利用7种炎症标志物的系统性炎症潜变量构建DNA甲基化替代生物标志物InfLaMeS,在HRS中评估其预测多病共存、失能和4年死亡率的性能,并与实测炎症标志物比较,结果在爱尔兰老龄化纵向研究中得到外部验证。

要点

  • InfLaMeS与7种炎症标志物相关(r=-0.2~0.6)。
  • InfLaMeS预测多病、失能和4年死亡率与系统性炎症潜变量相似或更强。
  • 结果在爱尔兰老龄化纵向研究外部队列中得到验证。

核心结论

  • InfLaMeS可作为实测血液炎症标志物的稳健替代指标,适用于有DNA甲基化数据但未测炎症标志物的研究。

研究设计与样本

  • 基于健康与退休研究(HRS)构建DNA甲基化替代生物标志物,并在爱尔兰老龄化纵向研究外部验证。

主要发现

  • InfLaMeS与7种个体炎症标志物相关(r=-0.2~0.6)。
  • 在HRS中,InfLaMeS预测多病共存、失能和4年死亡率与系统性炎症潜变量相似或更强。
  • 结果在爱尔兰老龄化纵向研究外部队列中得到验证。

关键数值与推荐

  • InfLaMeS由7种炎症标志物的系统性炎症潜变量构建。
  • InfLaMeS与7种个体炎症标志物相关系数r=-0.2~0.6。

临床怎么用

  • 在缺乏炎症标志物测量但拥有DNA甲基化数据的研究中,可用InfLaMeS替代评估慢性系统性炎症。
  • InfLaMeS可用于预测多病共存、失能和4年死亡率等年龄相关结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic low-grade systemic inflammation is a risk factor for chronic diseases and mortality and is an important biomarker in health research. DNA methylation (DNAm) surrogate biomarkers are valuable exposure, risk factor, and health outcome predictors in studies where the measures cannot be measured directly and often perform as well or better than direct measures. We generated a DNAm surrogate biomarker for chronic, systemic inflammation from a systemic inflammation latent variable of 7 inflammatory markers and evaluated its performance relative to measured inflammatory biomarkers in predicting several age-associated outcomes of interest, including mortality, activities of daily living, and multimorbidity in the Health and Retirement Study (HRS). The DNAm surrogate, Inflammation Latent Variable Methylation Surrogate (InfLaMeS), correlated with 7 individual inflammation markers (r = -0.2-0.6) and had similar or stronger associations with multimorbidity, disability, and 4-year mortality in HRS compared to the systemic inflammation latent variable measure when predicting multimorbidity, disability, and 4-year mortality in HRS. Findings were validated in an external cohort, the Irish Longitudinal Study of Ageing. These results suggest that InfLaMeS provides a robust alternative to measured blood-chemistry measures of inflammation with broad research applicability in instances where values of inflammatory markers are not measured but DNAm data are available.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Meier HCS, Klopack ET, Farnia MP, et al. A novel DNA methylation-based surrogate biomarker for chronic systemic inflammation (Inflammation Latent Variable Methylation Surrogate, InfLaMeS). J Gerontol A Biol Sci Med Sci. 2025. PMID: 40990779. doi:10.1093/gerona/glaf202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。